Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Tsveta Milanova Sells 2,804 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $35.12 on Wednesday. Agios Pharmaceuticals, Inc. has a 1 year low of $20.96 and a 1 year high of $62.58. The firm has a 50-day simple moving average of $47.15 and a two-hundred day simple moving average of $45.63. The company has a market cap of $2.00 billion, a P/E ratio of 3.09 and a beta of 0.87.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Royal Bank of Canada boosted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Scotiabank increased their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $60.00 to $56.00 in a research note on Friday, September 27th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $56.33.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of AGIO. Bank of New York Mellon Corp increased its stake in Agios Pharmaceuticals by 13.9% in the second quarter. Bank of New York Mellon Corp now owns 223,151 shares of the biopharmaceutical company’s stock worth $9,622,000 after purchasing an additional 27,193 shares during the period. TD Asset Management Inc increased its stake in Agios Pharmaceuticals by 34.6% in the 2nd quarter. TD Asset Management Inc now owns 210,472 shares of the biopharmaceutical company’s stock worth $9,076,000 after buying an additional 54,054 shares during the period. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter valued at about $37,000. Quest Partners LLC purchased a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $40,000. Finally, Headlands Technologies LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter worth about $494,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.